Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline

医学 指南 加药 养生 重症监护医学 内科学 儿科 病理
作者
Linan Zeng,Michael Walsh,Gordon Guyatt,Reed Siemieniuk,David Collister,Michelle Booth,Paul Brown,Lesha Farrar,Mark Farrar,Tracy Firth,Lynn A. Fussner,Karin Kilian,Mark A. Little,Thomas A. Mavrakanas,Reem A. Mustafa,Maryam Piram,Lisa K. Stamp,Yingqi Xiao,Lyubov Lytvyn,Thomas Agoritsas
标识
DOI:10.1136/bmj-2021-064597
摘要

Abstract Clinical questions What is the role of plasma exchange and what is the optimal dose of glucocorticoids in the first 6 months of therapy of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)? This guideline was triggered by the publication of a new randomised controlled trial. Current practice Existing guideline recommendations vary regarding the use of plasma exchange in AAV and lack explicit recommendations regarding the tapering regimen of glucocorticoids during induction therapy. Recommendations The guideline panel makes a weak recommendation against plasma exchange in patients with low or low-moderate risk of developing end stage kidney disease (ESKD), and a weak recommendation in favour of plasma exchange in patients with moderate-high or high risk of developing ESKD. For patients with pulmonary haemorrhage without renal involvement, the panel suggests not using plasma exchange (weak recommendation). The panel made a strong recommendation in favour of a reduced dose rather than standard dose regimen of glucocorticoids, which involves a more rapid taper rate and lower cumulative dose during the first six months of therapy. How this guideline was created A guideline panel including patients, a care giver, clinicians, content experts, and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. The recommendations are based on two linked systematic reviews. The panel took an individual patient perspective in the development of recommendations. The evidence The systematic review of plasma exchange identified nine randomised controlled trials (RCTs) that enrolled 1060 patients with AAV. Plasma exchange probably has little or no effect on mortality or disease relapse (moderate and low certainty). Plasma exchange probably reduces the one year risk of ESKD (approximately 0.1% reduction in those with low risk, 2.1% reduction in those with low-moderate risk, 4.6% reduction in those with moderate-high risk, and 16.0% reduction in those with high risk or requiring dialysis) but increases the risk of serious infections (approximately 2.7% increase in those with low risk, 4.9% increase in those with low-moderate risk, 8.5% increase in those with moderate-high risk, to 13.5% in high risk group) at 1 year (moderate to high certainty). The guideline panel agreed that most patients with low or low-moderate risk of developing ESKD would consider the harms to outweigh the benefits, while most of those with moderate-high or high risk would consider the benefits to outweigh the harms. For patients with pulmonary haemorrhage without kidney involvement, based on indirect evidence, plasma exchange may have little or no effect on death (very low certainty) but may have an important increase in serious infections at 1 year (approximately 6.8% increase, low certainty). The systematic review of different dose regimens of glucocorticoids identified two RCTs at low risk of bias with 704 and 140 patients respectively. A reduced dose regimen of glucocorticoid probably reduces the risk of serious infections by approximately 5.9% to 12.8% and probably does not increase the risk of ESKD at the follow-up of 6 months to longer than 1 year (moderate certainty for both outcomes). Understanding the recommendation The recommendations were made with the understanding that patients would place a high value on reduction in ESKD and less value on avoiding serious infections. The panel concluded that most (50-90%) of fully informed patients with AAV and with low or low-moderate risk of developing ESKD with or without pulmonary haemorrhage would decline plasma exchange, whereas most patients with moderate-high or high risk or requiring dialysis with or without pulmonary haemorrhage would choose to receive plasma exchange. The panel also inferred that the majority of fully informed patients with pulmonary haemorrhage without kidney involvement would decline plasma exchange and that all or almost all (≥90%) fully informed patients with AAV would choose a reduced dose regimen of glucocorticoids during the first 6 months of therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Rr完成签到,获得积分10
刚刚
脑洞疼应助555557采纳,获得10
2秒前
点到为止发布了新的文献求助10
2秒前
5秒前
啵噜噜噜啊完成签到,获得积分10
8秒前
OYY完成签到 ,获得积分10
8秒前
烂漫的断秋完成签到 ,获得积分10
9秒前
10秒前
10秒前
Lucas应助Livrik采纳,获得10
11秒前
cyn0762完成签到,获得积分10
11秒前
点到为止完成签到,获得积分10
12秒前
13秒前
Akim应助lll采纳,获得10
14秒前
高贵灵槐完成签到 ,获得积分10
15秒前
18秒前
wxh完成签到 ,获得积分20
18秒前
量子星尘发布了新的文献求助10
18秒前
liuzi发布了新的文献求助20
19秒前
雨过天晴完成签到,获得积分10
20秒前
花花完成签到 ,获得积分10
21秒前
22秒前
24秒前
汪汪发布了新的文献求助10
27秒前
27秒前
28秒前
31秒前
追寻筮关注了科研通微信公众号
31秒前
miaojuly发布了新的文献求助10
32秒前
充电宝应助汪汪采纳,获得10
33秒前
34秒前
涵哈哈哈哈哈完成签到 ,获得积分10
36秒前
38秒前
liuzi完成签到,获得积分10
38秒前
科目三应助油菜的星星采纳,获得10
40秒前
40秒前
40秒前
41秒前
41秒前
木心应助高院士采纳,获得60
42秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035